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ABSTRACT
Increased density of tumor-associated lymphatic vessels correlates with poor patient survival in melanoma
and other cancers, yet lymphatic drainage is essential for initiating an immune response. Here we asked
whether and how lymphatic vessel density (LVD) correlates with immune cell inﬁltration in primary tumors
and lymph nodes (LNs) from patients with cutaneous melanoma. Using immunohistochemistry and
quantitative image analysis, we found signiﬁcant positive correlations between LVD and CD8C T cell
inﬁltration as well as expression of the immunosuppressive molecules inducible nitric oxide synthase
(iNOS) and 2,3-dioxygenase (IDO). Interestingly, similar associations were seen in tumor-free LNs adjacent
to metastatic ones, indicating loco-regional effects of tumors. Our data suggest that lymphatic vessels play
multiple roles at tumor sites and LNs, promoting both T cell inﬁltration and adaptive immunosuppressive
mechanisms. Lymph vessel associated T cell inﬁltration may increase immunotherapy success rates
provided that the treatment overcomes adaptive immune resistance.
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Introduction
Over the last two decades, burgeoning research attention
has been focused on understanding the complex interac-
tions between evolving tumors and host immune responses,
with consequences for the development of novel immuno-
therapies.1-4 Despite the promotion of tumor antigen spe-
ciﬁc T cell responses by active immunization, checkpoint
blockade or adoptive transfer, only a subset of patients
experience clinical beneﬁt.5 In melanoma, recent studies
have sought predictive indicators (genetic or phenotypic) by
comparing patients who respond to immunotherapies with
those that do not.6,7 A variety of factors have been found to
affect response to immunotherapy, including the preexisting
immune cell inﬁltrate and the chemokine expression pro-
ﬁle.8,9 Furthermore, cancers can develop adaptive immune
resistance mechanisms that suppress anti-tumor T cell
responses.10,11 In addition, further mechanisms may con-
tribute to therapy failures, including mechanisms that
impact on the recruitment of immune cells to tumors.12
New and readily accessible/quantiﬁable biomarkers are
required to help identifying the underlying reasons in indi-
vidual patients, and consequently adapt immune therapy
strategies in order to increase patient survival.13
One feature of many cancers is the activation or expansion
of lymphatic vessels. Local lymphatic vessel density (LVD) is
known to be associated with metastasis in several human and
experimental cancers. The lymphangiogenic factor Vascular
Endothelial Growth Factor-C (VEGF-C), secreted by tumor-
associated macrophages or tumor cells themselves, leads to
increased LVD in the tumor microenvironment and in lymph
nodes (LNs), correlating with increased metastasis and poor
prognosis.14-20 However, the mechanisms by which lymphan-
giogenesis promotes disease progression are not well under-
stood. While increased LVD provide more surface area for
tumor cells to enter the lymph and thereby migrate to distant
sites, recent studies have highlighted additional important
mechanisms. For example, VEGF-C activates lymphatic endo-
thelial cells (LECs) to upregulate chemokine (C-C motif) ligand
21 (CCL21), a chemo-attractant for C-C chemokine receptor
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7C (CCR7) immune cells and tumor cells, leading to increased
tumor invasion and entry into lymphatics in vitro and in
mice.21-23 More recently, it has been proposed that lymphan-
giogenesis could play important roles in modulating the
immune microenvironment. In mouse models, increased
CCL21 in the tumor microenvironment could promote ﬁbro-
blast differentiation and matrix remodeling to resemble the
stroma of lymph nodes, as well as promote T cell inﬁltration
(including regulatory T cells) along with suppressive leukocyte
subsets.24 Furthermore, tumor-associated LECs may directly
cross-present tumor antigens to CD8C T cells and render them
dysfunctional in the tumor microenvironment.25,26 LECs can
also inhibit the maturation of dendritic cells,27 secrete inhibi-
tory molecules such as indoleamine 2,3-dioxygenase (IDO),
inducible nitric oxide synthase (iNOS) and transforming
growth factor beta (TGF-b), and impair T cell activation
through expression of inhibitory receptor ligands (e.g. pro-
grammed cell death ligand 1 and 2 (PD-L1 and 2)).28 Finally, a
recent study demonstrated that in mice lacking dermal lym-
phatic vessels, melanomas failed to generate an inﬂammatory
microenvironment and lacked T cell inﬁltration.29 Taken
together, these ﬁndings indicate a critical role for tumor-associ-
ated lymphatics in initiating and shaping the immune response.
Since these studies were performed in mice, in short-
term studies with implanted tumors, we asked whether and
how LVD correlates with the immune microenvironment in
patients with cutaneous melanoma. Through immunohis-
tochemistry (IHC) analysis of primary tumors and down-
stream LNs, using a dedicated method enabling quantitative
assessment of unusually large tissue ﬁelds, we provide evi-
dence that LVD indeed correlates with T cell inﬁltration
and expression of immune suppressive molecules in human
melanoma, not only locally but also in regional LNs, includ-
ing in those that are not (yet) metastatic. Our ﬁndings sug-
gest that while LVD and VEGF-C are prognostic factors for
metastasis, they also are tightly correlated with the immune
status of the tumor microenvironment and thus may have
potential impact on the outcome of immunotherapy.
Results
Quantiﬁcation of lymph vessels across entire tissue
sections
To determine LVD we examined LECs by IHC staining in sec-
tions of tumors and draining LNs. We found high variability of
LVD in different regions of the tumor, as well as high inter-
patient heterogeneity. Thus, we ﬁrst sought to establish a
method of analyzing entire tumor sections for very wide and
representative spatial assessment of LVD and related features
of the immune microenvironment. We deﬁned distinct tissue
zones in the tumor and LN microenvironments to study 13 pri-
mary tumors, 23 metastatic LNs and 23 tumor-free LNs (i.e.
neighboring distant lymph node without evidence of disease)
and used whole-slide imaging software for quantiﬁcations in
each zone (see Methods).
To deﬁne the localization of LECs in different human
tissue sections we performed IHC using Prox-1 and podo-
planin antibodies. Histological analysis conﬁrmed that
podoplanin was speciﬁcally expressed on lymphatic vessels
in different zones of the primary tumor (Fig. 1A), the
tumor region of metastatic LNs (Fig. 1B) and the normal
skin (Fig. S1A). In contrast, Prox-1 antibody was not well
suited as LEC marker within these tissues, as certain tumor
cells as well as skin epithelial cells may also be positive
(Fig. 1A and B and Fig. S1A and B).
Up to now, histological quantiﬁcation of human lym-
phatic vessels was mainly done by the so-called “hot spot”
analysis30 which usually considers only small tissue regions
where density of lymphatic vessels was the highest. In con-
trast, our approach consisted of automated marker quantiﬁ-
cation in large but distinct tissue areas based on staining
intensity. In order to validate the automated marker quanti-
ﬁcation method and characterize the best marker to identify
LECs in the individual tissues, we performed automated
quantiﬁcation of Prox-1 and podoplanin, respectively, and
correlated the results with our data from LEC counting by
eye (see “LEC quantiﬁcation” in Methods). We found that
podoplanin quantiﬁed by automated whole tissue analysis
correlated well with lymphatic vessels quantiﬁed per mm2
by counting by eye in the different regions of the primary
tumor (Fig. 1A) and in the tumor region of metastatic LNs
(Fig. 1B). In agreement with our visual observation, auto-
mated quantiﬁcation of Prox-1 did not correlate signiﬁ-
cantly with LEC counting by eye in primary tumor
(Fig. 1A) and only minor in the tumor region of metastatic
LNs (Fig. 1B) whereas the correlation for podoplanin was
strong. In contrast to tumor bearing tissues, LEC quantiﬁca-
tion in tumor-free LNs was superior based on Prox-1 stain-
ing as compared to podoplanin staining, because
podoplanin was also expressed by several other cell types in
the lymph nodes, for example follicular dendritic cells
(Fig. S1C). Indeed, automated quantiﬁcation of Prox-1
showed a good correlation with the LEC counting by eye in
tumor-free LNs (Fig. S1D). The combined use of both,
Prox-1 and podoplanin by Immunoﬂuorescence (IF) label-
ing conﬁrmed the validity of our strategy to identify LECs
in the different tissues analyzed (Fig. 1C). Therefore, based
on these results, we chose for our broad quantiﬁcation of
LECs to use podoplanin expression in primary tumors and
the tumor regions of metastatic LNs, and Prox-1 expression
in tumor-free LNs.
Increased intratumoral lymph vessel density (LVD)
and VEGF-C in earliest stages of primary melanoma
High LVD has been previously described in prominent “hot
spots” both within and around primary cutaneous malignant
melanoma.31 Moreover, melanoma lesions have been shown to
have higher intratumoral and peritumoral LVD compared to
benign melanocytic lesions, likely due to pro-lymphangiogenic
factors, essentially VEGF-C, secreted by tumor cells.32-34
Detailed analysis of the distribution of LECs in primary tumors
showed that LVD was already increased in the earliest stage of
melanoma (melanoma in situ) in comparison to the adjacent
normal skin. Furthermore our data conﬁrmed that LVD is
increased in primary melanoma, speciﬁcally in the invasive
margin and the peritumoral regions (Fig. 2A). In order to
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determine the presence of VEGF-C and its association with
LEC formation and distribution we performed immunostaining
of VEGF-C in primary tumors and metastatic lymph nodes.
Podoplanin positively correlated with VEGF-C only within
melanoma in situ (Fig. 2B) while in primary melanoma and in
the tumor regions of metastatic LNs these parameters did not
correlate (Fig. S2A-F). These results are compatible with the
notion that VEGF-C may play a role in lymphangiogenesis in
early stage of melanoma formation.
LVD correlates with tumor inﬁltrating CD8C T cells
and expression of immune suppressive molecules
To investigate the potential associations of LVD with immune
cell inﬁltrates, we next quantiﬁed the density of inﬁltrating lym-
phocytes expressing CD8, CD4, Foxp3 and CD19. Since LNs
are important sites for tumor spread and immune responses,
we not only analyzed the immune microenvironment of pri-
mary tumors, but also the one of the tumor regions within
Figure 1. Comparison of lymph vessel density (LVD) assessment by automated pixel based large-scale quantiﬁcation versus LEC counting by eye. Representative immuno-
histochemistry images showing podoplanin and Prox-1 staining of peritumoral area (PT), invasive margin (IM) and center of tumor (CT) of A) primary melanoma and B)
stroma and tumor regions of metastatic lymph node sections (Scale bars in A) 500 mm; in B) 1mm). Correlations of podoplanin or Prox-1 (% of pixel positive cells) counted
by the ImageScopeTM software (x-axis) versus counted by eye (y-axis) in IM (n D 12), CT (n D 11) and PT (n D 12) of primary tumors and in tumor regions of metastatic
LNs (n D 22). C) Representative immunoﬂuorescence images of podoplanin (green) and Prox-1 (red) co-localization in different tissues (20X, scale bar D 50 mm, DAPI,
blue). All correlations were analyzed using non-parametric Spearman’s test. (PT): peritumoral area, (IM): invasive margin, (CT): center of tumor.
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metastatic LNs. Interestingly, similar to the distribution of
LECs we found the highest density of CD8C T cells in peritu-
moral areas and the invasive margin of primary tumors
(Fig. 3A). Quantitative analysis revealed that primary tumors
showed strong positive correlations of CD8C T cell inﬁltration
with LVD (Fig. 3B). This correlation held true in all primary
tumor regions analyzed (center of tumor, invasive margin and
peritumoral regions). However, LVD showed only positive
trends not reaching statistical signiﬁcance for CD4C cells,
CD19C cells and FoxP3C regulatory T cells within primary
tumors (Fig. S3A-C). A strong positive correlation between
LVD and CD8C T cells was also found in metastatic LNs
(Fig. 3C). In contrast to primary tumors, in metastatic LNs we
found positive associations between LVD and CD19C cells and
also with FoxP3C cells (Fig. 3D), suggesting attraction of poten-
tially immune suppressive cells by mechanisms involving lym-
phatic vessels. Together, these data propose that
lymphangiogenic regions within the tumor may speciﬁcally
chemoattract circulating T cells, consistent with studies in
mouse melanoma, where VEGF-C was shown to upregulate
CCL21 to attract CCR7C immune cells.24
Next, we investigated the correlation of LVD with the pres-
ence of immune suppressive factors by analyzing the expression
of iNOS, IDO, and arginase-1 (Arg-1) in the same tissues. IF
analysis revealed that both iNOS and IDO were mainly pro-
duced by cells surrounding lymphatic vessels rather than by the
LECs in primary tumors (Fig. 4A, left panels). However, we
found iNOS expression in the cytoplasm of LECs in metastatic
LNs (Fig. 4A, right panels) suggesting that tumor-associated
LECs can play direct roles in immune modulation. LVD posi-
tively correlated with iNOS expression in the invasive margin,
and with IDO expression in the center of tumor (Fig. 4B, left
panels). In the tumor region of metastatic LNs, iNOS and IDO
expression were positively correlated with LVD (Fig. 4B, right
panels). Arg-1 was neither expressed by LECs nor associated
with LVD in any of the melanoma tissues analyzed (Fig. S4A
and B).
VEGF-C correlates with T cell inﬁltration in primary
melanoma and immune suppressive molecules in early
stages of primary melanoma and metastatic LNs
Mouse melanomas have been reported to pre-condition future
sites of LN metastasis by enhancing lymphangiogenesis, induc-
ing an immune tolerant microenvironment and thus impairing
the development of anti-tumor immunity.35,36 Furthermore,
VEGF-C overexpression in mouse melanoma promoted an
immune suppressive microenvironment in primary and down-
stream LNs.24,25 To address the potential role of VEGF-C in
modulating host anti-tumor immunity in human melanoma,
we quantiﬁed tumor sections immunostained for VEGF-C and
immune markers. Interestingly, in the earliest stages of primary
melanoma (melanoma in situ), we found strong positive corre-
lations between VEGF-C expression and iNOS (Fig. 5A).
Increased expression of VEGF-C correlated with elevated
expression of iNOS and IDO in tumor regions of metastatic
LNs (Fig. 5B-C). These results suggest that VEGF-C may have
different roles in modulating the tumor microenvironment
(TME) depending on tumor stage and tissue location.
LVD correlates with CD8C T cells and immune suppressive
molecules in tumor-free LNs adjacent to metastatic LNs
Mouse studies have suggested that melanomas can secrete fac-
tors that pre-condition potential future metastatic sites in LNs,
and that this pre-conditioning is associated with increased
LVD.35,36 Studies in humans have shown immunological differ-
ences in LNs close to the primary melanoma as compared to
the more remote LNs, with regard to the capacity of paracorti-
cal dendritic cells and T cells to inhibit or enhance melanoma
cell growth in vitro, as well as the density of high endothelial
venules (HEVs).37 To identify possible changes in distal LNs in
our patients, we analyzed 23 tumor-free LNs, with the hypothe-
sis that tumor-free LNs may differ depending on whether they
were from LN dissections with one or more metastatic LNs
Figure 2. Increased lymphatic vessel density (LVD) in melanoma in situ, invasive margin and peritumoral area of primary melanomas. A) Quantiﬁcation of podoplanin den-
sity (% of pixel positive cells) in normal skin (NS; n D 12), melanoma in situ (MIS; n D 14) and in the different histological zones of primary melanomas, i.e. peritumoral
region (PT; n D 13), invasive margin (IM; n D 13) and center of tumor (CT; n D 12). Line indicates median. , p  0.001; , p  0.01; one-way Kruskal-Wallis non-
parametric test with post-hoc test Dunn correction. B) Correlation of podoplanin with VEGF-C density (% of pixel positive cells) in melanoma in situ (n D 13). Correlation
was analyzed using non-parametric Spearman’s test.
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(tumor-positive LN dissection; n D 14) versus dissections
where all LNs were tumor-free (tumor-negative LN dissection;
n D 9). Interestingly, tumor-free LNs from positive LN dissec-
tions had higher expression of Prox-1 as compared to LNs
from negative LN dissections (Fig. 6A). Greater densities of
CD8C cells and CD4C cells were seen in LNs from tumor-
positive LN dissections compared to negative LN dissections
(Fig. 6B). In line with this, higher density for iNOS and Arg-1
were found in LNs from positive LN dissections (Fig. 6C).
Interestingly, in tumor-free LNs from positive LN dissections,
LECs were found to express iNOS (Fig. 6D), showing a positive
correlation with iNOS expression (Fig. 6E) similar to that in
Figure 3. LVD correlates with inﬁltration of CD8C T cells in primary tumors and tumor regions of metastatic lymph nodes (LNs). A) Quantiﬁcation of CD8 density (% of
pixel positive cells) in different zones of primary melanomas. Statistical signiﬁcance was calculated using one-way Kruskal-Wallis non-parametric test with post-hoc test
Dunn correction. Line indicates median. , p  0.001; , p  0.01; , p  0.05. Representative immunoﬂuorescence images showing lymphatic vessels (Prox-1, red;
podoplanin, green) and CD8C T cells (grey) in lymphatic-poor and -rich regions of a B) primary tumor and a C) metastatic LN (20X, Scale bar D 50 mm, DAPI, blue). Corre-
lations of podoplanin with CD8 density (% of pixel positive cells) in PT (n D 13), IM (n D 13) and CT (n D 13) of B) primary tumors and in C) metastatic LNs (n D 23). D)
Correlations of podoplanin with CD19 (n D 21) and FoxP3 (n D 22) density (% of pixel positive cells) in tumor regions of metastatic LNs. All correlations were analyzed
using non-parametric Spearman’s test. (PT): peritumoral region, (IM): invasive margin, (CT): center of tumor.
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metastatic LNs (Fig. 4B). Together, these data indicate that
tumor-free LNs adjacent to metastatic LNs have increased
LVD, lymphocyte density and immunosuppressive features
compared to LNs from tumor negative LN dissections.
Discussion
Multiple studies have demonstrated the clinical relevance of
tumor-associated lymphatics and their involvement in malig-
nant spread.38-40 In human melanoma, increased intra-
and peritumoral LVD as well as the lymphatic growth
factor VEGF-C strongly correlate with metastatic
dissemination.17,33,41-43 Lymphatic vessels may support migra-
tion of tumor cells, but may also modulate immune cells, as
recently demonstrated in primary tumors and draining LNs in
mice,24,25,44 raising the possibility that lymphatics mediate
immune suppression and poor clinical outcome in cancer
patients.19,31,42 Because corresponding human data are missing,
we performed a very wide IHC analysis. Our ﬁndings reveal
multiple correlations between lymphatic vessels and host
immunity, suggesting immune mechanisms that act locally as
well as loco-regionally in melanoma patients (Fig. 7).
Figure 5. VEGF-C is associated with expression of immune suppressive molecules in melanoma in situ and tumor regions of metastatic LNs. A) Correlations of VEGF-C with iNOS
density (% of pixel positive cells) in melanoma in situ (nD 14). B) Representative immunohistochemistry images showing iNOS and IDO expression in tumor region of VEGF-C-low
and VEGF-C-high metastatic LN sections (Scale barD 100mm). C) Correlations of VEGF-C with iNOS (nD 23) and IDO (nD 23) density (% of pixel positive cells) in tumor regions of
metastatic LNs. Correlations were analyzed using non-parametric Spearman’s test. (IM): invasive margin, (CT): center of tumor, (PT): peritumoral region.
Figure 4. LVD correlates with expression of immune suppressive molecules in primary tumors and tumor regions of metastatic LNs. A) Representative immunoﬂuores-
cence images in a section of a primary tumor and a metastatic LN showing that intratumoral lymphatic vessels (Prox-1, red; podoplanin, green) express iNOS (white,
arrows) in metastatic LNs and do not express IDO (grey) in either location (63X upper panels Scale bar D 10 mm, and 40X lower panels, Scale bar D 50 mm, DAPI, blue).
B) Correlations of podoplanin with iNOS and IDO density (% of pixel positive cells) in IM (n D 13), CT (n D 12) and PT (n D 13) of primary tumors and in metastatic LNs (n
D 23). Correlations were analyzed using non-parametric Spearman’s test. (IM): invasive margin, (CT): center of tumor, (PT): peritumoral region.
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A standard methodology of lymphatic vessel quantiﬁcation
is based on the observation that lymphatics form areas of
increased LVD density.45 The majority of studies on LVD and
clinical outcome of melanoma patients have used staining
quantiﬁcation methods based on visual inspection and selection
of “hot spots” (e.g. Weidner and Chalkley method).32,46,47
Despite the recent emergence of computer-assisted image anal-
ysis that reduces the variability and subjectivity in quantifying
lymphatics, many studies are still based on either selected “hot
spot” regions or randomly selected ﬁelds.16,43 We analyzed
Figure 6. Tumor-free LNs that are adjacent to metastatic LNs have higher LVD, T cell inﬁltration and immune suppressive molecules than LNs from completely tumor-free
LN-regions. Tumor-free LNs from negative LN dissections (neg. LN diss.; n D 9) were compared with tumor-free LNs from positive LN dissections (pos. LN diss.; n D 14).
Density of A) lymphatic vessels, B) T cells and C) the immune suppressive molecules iNOS and Arg-1 (% of pixel positive cells). Line indicate median; data were analyzed
with the unpaired t-test for normally distributed data sets and with a nonparametric unpaired Mann-Whitney U test for data sets that were not normally distributed. D)
Representative immunoﬂuorescence images showing that intratumoral lymphatic vessels (Prox-1, red and podoplanin, green) mainly expressed iNOS (white, arrow) in
tumor-free LNs from positive LN dissections. Scale bars D 50mm, Arrow bar highlighting lymphatic vessel structures. E) Correlations of Prox-1 with iNOS in tumor-free
LNs from negative and positive LN dissections (% of pixel positive cells). Correlations were analyzed using non-parametric Spearman’s test.
Figure 7. Increased lymphatic vessels density is associated with increased CD8+ T cell inﬁltration, together with increased expression of immunosuppressive molecules
such as iNOS, IDO and Arg-1. This can be observed not only locally in primary tumors and metastatic lymph nodes (LNs) but also in adjacent non-metastatic LNs. Together,
tumor derived VEGF-C induces lymphatic vessels that attract CD8+ T cells, with their known fundamental properties, namely the promotion of anti-tumor immune
responses but also immune suppression (via adaptive immune resistance mechanisms).
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speciﬁc regions as well as entire sections of different mela-
noma-associated tissues with a dedicated image analysis soft-
ware, allowing quantitative assessment of unusually large tissue
areas in a reproducible manner. Speciﬁcally, we used the pixel
count algorithm (ImageScopeTM, Aperio) for large-scale quan-
tiﬁcation of lymphatics, lymphocytes and immune suppressive
molecules. Pixel-based analysis has been validated as an accu-
rate strategy for the assessment of cell density in tissue sec-
tions,48 and may be more precise than cell-counting
algorithms, especially in the setting of dense and relatively
homogenous cell populations such as within the tumor mass.
In agreement with our ﬁndings, increased LVD has been
described in and around primary melanomas compared to mel-
anocytic nevi and normal dermis.32-34 We did not ﬁnd statisti-
cally signiﬁcant differences between intra- (either center of
tumor or invasive margin) or peri-tumoral LVD as described
by some46,49,50 but not other studies.43,51 Possible reasons for
discrepancies could be the use of different image analysis and/
or staining quantiﬁcation strategies.
Many reports established the role of VEGF-C in promoting
lymphangiogenesis and LN metastases in murine and human
tumors.52 Nonetheless, VEGF-C expression did not always corre-
late with LVD in cutaneous melanoma.46 Surprisingly, we found
that VEGF-C correlated with LVD only in the earliest stage of pri-
mary melanoma. This suggests that VEGF-C mainly promotes
lymphangiogenesis early in the development of the tumor.
Recently it was shown that tumor-associated lymphangio-
genesis mediated intratumoral T cell inﬁltration in mice.29 Our
ﬁndings indicate that similar mechanisms are in place in
humans, because LVD strongly correlated with CD8C T cell
inﬁltration in primary cutaneous melanoma as well as in metas-
tases of draining LNs. Interestingly, these associations were
found in the three different zones delimited in the primary
tumor sections, implying that lymphatic activation may pro-
mote accumulation of CD8C T cells not only around but also
within the tumor mass.
Besides LECs, tertiary lymphoid structures (TLSs) are important
components of tumor-associated immune functions. TLS are of
increasing interest in tumor immunology because they are often
associated with anti-tumor T cell responses and favorable progno-
sis of cancer patients.53 Although high endothelial venules (HEVs)
have been described in primary melanoma and have been linked to
good clinical outcome,54,55 conﬂicting results exist in regard to the
presence of TLSs in primary melanoma, in spite of the fact that the
latter frequently containHEVs.56,57While we found a positive asso-
ciation between lymphatics and CD19C cells in metastatic LNs, we
did not detect many B cell clusters in the tumor samples examined
here. The increased inﬁltration of B cells in association with lym-
phatic vessels in metastatic LNs may support the notion that lym-
phatics promote also the humoral immune response. Further
investigations are required to elucidate the interactions between
lymphatics and B cells, and their roles in cancer patients.
LECs can affect T cell fate as well as suppress dendritic cell-
mediated T cell activation by secreting a variety of immune
suppressive factors such as TGF-b, IDO and iNOS.58 Kornek
et al. reported that in vitro-expanded murine LECs mediated
direct suppression of T cell proliferation, essentially depending
on IFN-g from activated T cells.59 N€order et al. demonstrated
that human in vitro IFN-g activated LECs produced IDO which
suppressed T cell activation.60 Compatible with these in vitro
studies, we observed signiﬁcant associations between LVD and
iNOS expression at the invasive margin and IDO expression in
the center of tumor of primary melanomas, but also found sig-
niﬁcant correlations with CD8C T cell inﬁltration.
In concert with primary tumors, our study identiﬁes immune
suppressive molecules in tumor-draining LNs, suggesting that
immune mechanisms operating in metastatic LNs25,37,61,62 may at
least in part be similar to those in primary tumors.63 In contrast to
primary tumors, we found a signiﬁcant correlation between LECs
and FoxP3C lymphocytes. The question of whether regulatory T
cells play an important role in melanoma progression andmetasta-
sis formation is still unanswered, and conﬂicting data have been
reported with regard to clinical impact.64
Several studies have identiﬁed alterations in both local and
regional immune functions of metastatic LNs that may contrib-
ute to tumor expansion and metastasis formation.37 However,
only limited data exist showing possible effects of nearby
metastases on immune functions of tumor-free LNs. Zucker-
man et al. examined differences in immune cell signatures
between tumor-free LNs of node negative breast cancer patients
and tumor-invaded sentinel lymph nodes (SLNs), tumor-free
SLNs or tumor-free non-sentinel lymph nodes (NSLNs) of
node positive breast cancer patients.65 This study provided the
ﬁrst evidence of altered immune regulation depending on
whether neighboring LNs were metastatic or not. We investi-
gated the immunological differences between tumor-free LNs
from patients with positive versus negative LN dissections. Our
data show that the tumor-free LNs from tumor-positive LN
dissections had higher densities of LECs, T lymphocytes, iNOS
and Arg-1, as compared to those from negative LN dissections,
arguing that lymphatics may impact on immune regulation
beyond the TME and prior to metastasis formation.
Together, we describe novel associations between LECs,
lymphocytes and immune suppressive molecules within differ-
ent tissues of melanoma patients. LECs were positively associ-
ated with locally enhanced CD8C T cell inﬁltration as well as
iNOS and IDO expression within primary melanoma tissues
and in metastatic LNs. Tumor-free LNs showed similar associa-
tions, pointing to loco-regional effects. These results support
the view that LECs are active modulators of anti-tumor
immune responses within different human melanoma tissues.
Our results should be validated in larger numbers of patients.
Furthermore, as our study could only reveal correlations, fur-
ther studies will be needed to reﬁne the underlying mecha-
nisms, e.g. by ex-vivo functional analysis combined with
systems biology approaches and mechanistic mouse studies.
A major aim in the development of cancer immunotherapies is
to overcome suppression of anti-tumor T cell responses. Our study
suggests that LECs are implicated in the recruitment and attraction
of CD8C T cells as well as the expression of immune suppressive
molecules. Therefore, LECs likely support both, promote and hin-
der anti-tumor T cell responses. Of note, the presence of a T cell-
inﬂamed tumor microenvironment is indicative of an endogenous
adaptive immune response against a given tumor, and is emerging
as a useful predictive biomarker for response to immunotherapy.66
Indeed, it was recently shown that highly inﬁltrated and lymphan-
giogenic murine tumors were more sensitive to immunotherapy,
by recruiting T cells and antigen presenting cells through the
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CCL21-CCR7 axis. Furthermore, serum VEGF-C was found to
correlate with antitumor T cell responses and progression free sur-
vival of melanoma patients treated with immunotherapy.67 Finally,
therapeutic induction of lymphoid structures synergized with
immunotherapy in mice.68 Thus, novel combination immuno-
therapies may include the promotion of lymphatics despite that
they are also implied in immune suppressivemechanisms andmet-
astatic spread. Future therapy improvements may depend on the
successful increase of the beneﬁcial roles of lymphatics with simul-
taneous reduction of their negative effects.
Patients and methods
Patients
This study investigated 29 metastatic melanoma patients that
had been included in a phase I vaccination trial (LUD 00–018
study, ClinicalTrials.gov Identiﬁer NCT00112229) at the
Ludwig Cancer Research Center (LICR, University Hospital,
Lausanne, Switzerland) between 2003 and 2011 (Table S1), as
described previously.69,70 Brieﬂy, 29 HLA-A2C patients with
histologically proven metastatic melanoma of the skin express-
ing Melan-A/MART-1 received 1–4 cycles of monthly subcuta-
neous vaccinations with 100 mg Melan-A/MART-1 A27L
analog or native peptide (§ a Tyrosinase peptide) and CpG-
7909 (500 mg PF-3512676/7909; provided by Pﬁzer/Coley
Pharmaceutical Group) emulsiﬁed in incomplete Freund’s
adjuvant (300–600 ml Montanide ISA-51; provided by Seppic).
The patients were evaluated for treatment toxicity, immune
response (CD8C T cell response), tumor response and survival
(Table S2). Of the 29 patients included in the study, 25 were
selected for the present analysis and 4 were excluded (one
patient had uveal melanoma and three patients did not have
any FFPE tissues available). 19 primary melanoma samples
from 15 patients, 33 metastatic LNs from 14 patients (23 meta-
static LNs were taken before the vaccination and 10 metastatic
LNs were taken long after the end of the vaccination trial) and
23 tumor-free LNs from 20 patients (17 tumor-free LNs were
taken before the vaccination and 6 tumor-free LNs were taken
long after the end of the vaccination trial) were obtained and
were analyzed for their lymphocyte populations, lymphatic ves-
sels and immunosuppressive molecules. 14 tumor-free LNs
from 12 patients were from tumor-positive LN dissection and 9
tumor-free LNs from 8 patients were from tumor-negative LN
dissection. The study was approved by the Ethics Committee of
Canton of Vaud and the regulatory authorities, and conducted
in compliance with all legal and regulatory requirements.
Immunohistochemistry (IHC)
Chromogenic IHC staining
4-mm tick tissue sections of patient’s formalin-ﬁxed paraf-
ﬁn-embedded (FFPE) tissue specimen’s were ﬁrst deparafﬁ-
nised in xylene and rehydrated by sequential incubation in
EtOH/water solutions. Tissues were then treated with 3%
H2O2 in distilled water for 5 minutes to quench endogenous
peroxidase activity. Heat-induced antigen retrieval was per-
formed in Tris-EDTA buffer (pH 9) for 103000 in a steamer.
Subsequently, sections were incubated at room temperature
with primary antibodies to CD8 (clone C8/144b, Dako,
1:30, 32 min), CD4 (clone 4B12, Novocastra, 1:10,
90 minutes), CD19 (clone BT51E, Novocastra, 1:50,
32 min), FoxP3 (clone 236a/E7, Abcam, 1:50, 60 min),
podoplanin (clone D2-40, Covance, 1/400, 60 min), Prox-1
(R&D, 1:100, 32 min), VEGF-C (Invitrogen, 1:20, 40 min),
IDO (from Brussels, 1:500, 40 min), iNOS (Thermoscien-
tiﬁc, 1:75, 40 min), Arg-1 (Mybiosource, 1:300, 40 min),
Melan-A (clone A103, Dako, 1:50, 32 min), melanosome
(clone HMB45, Dako, 1:50, 32 min) and S100 (Novocastra,
1:800, 40 min) followed by a secondary anti-mouse (K4001,
Dako), anti-rabbit (DK4003, Dako) or anti-goat antibody
(Histoﬁne RTU-Biosciences) RTU/HRP ENVISION for
30 minutes. 3-amino-9 ethylcarbazole (AEC) was used as a
red chromogen (K3464, Dako) for CD4, S100, Melan-A and
melanosome and Diaminobenzidine (DAB, K3468, Dako) as
a brown chromogen (K3468, Dako) for the rest of the anti-
bodies. After rinsing with water, sections were counter-
stained with Hematoxylin Gill II (Merck 1.05175) and
coverslipped with xylol. CD8, CD4, CD19, FoxP3, podopla-
nin, Prox-1, Melan-A, S100 and Melanosome were done on
Ventana BenchMark machine using Cell Conditioning 1
(CC1, 950-124, Ventana) as a buffer for heat-induced anti-
gen retrieval with varied time for the different antibodies,
other reagent and time was done as described above. iNOS,
VEGF-C, Arg-1 and IDO stainings were done manually by
the technician with the above-mentioned protocol. Positive
controls included tonsil, lung, liver and colon. Immunos-
tainings with appropriate isotype control antibodies were
used as negative controls. For illustration purpose, represen-
tative images of the different stainings were taken from
tumor-free LNs (Fig. S5).
Conventional immunoﬂuorescence (IF) staining
As for chromogenic IHC staining, 4-mm tick tissue sections
were ﬁrst deparafﬁnised in xylene and rehydrated by sequential
incubation in EtOH/water solutions. Antigen retrieval was per-
formed by 15 minute incubation in boiling Tris-EDTA buffer
(pH 9), following 30 minutes incubation in blocking solution
(TBSC0.01% Triton X-100C2%BSAC2%total serum from host
secondary antibody). Sections were incubated overnight at 4C
with primary antibodies to CD8 (clone C8/144b, Dako, 1:30),
podoplanin (clone D2-40, Covance, 1/200), Prox-1 (R&D,
1:100), iNOS (Thermoscientiﬁc, 1:75), Arg-1 (Mybiosource,
1:300), IDO (from Brussels, 1:500), CCL21 (Atlas antibodies,
1:200) and PD-L1 (Cell Signaling, 1:200). Alexa Fluor 488-
labeled donkey anti-mouse IgG (Invitrogen, 1:400), 568-labeled
donkey anti-goat IgG (Invitrogen, 1:600) and 647-labeled don-
key anti-rabbit IgG (Invitrogen, 1:800) antibodies were used as
secondary antibodies and incubated for 1 hour at room temper-
ature. After stringent washes, sections were counterstained with
DAPI (Vector Laboratories, Burlingame, CA) for 5 minutes and
coverslipped with mounting medium (Vectashield mounting
media). Positive controls were done on tonsils, LNs and skin
tissues. Negative slides used TBS instead of primary antibody,
with other conditions constant. Images were obtained with
confocal microscope ZEISS LSM 700 UPRIGHT.
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Image analysis
In primary melanoma, four relevant histological regions
were deﬁned: invasive margin (IM, deﬁned as a tumor
region of about 400-mm width between the tumor and the
reticular dermis), center of tumor (CT), peritumoral region
(PT, deﬁned as a region of about 400-mm width in the der-
mis surrounding the invasive margin), and normal skin
(NS, determined as a region of about 200-mm width sepa-
rated by at least 1mm from tumor cells), as illustrated in
Fig. S6A. IM, CT and PT were present in 13 sections of the
19 primary melanoma selected and analyzed (Table S3).
The other 6 primary melanoma samples, the tumor mass
were too small or conﬁned in the epidermis such that these
three zones could not be deﬁned. Normal skin was identi-
ﬁed in 12 primary tumor samples. We also selected 14 sec-
tions from 10 melanoma patients where tumor cells were
still conﬁned in the epidermis and have not grown deeper.
Those are referred to as melanoma in situ (Table S3).
Tumor cells were identiﬁed based on Melan-A, Melanosome
(HMB45) and S100 positive staining or morphological crite-
ria (large atypical and pleomorphic cells with abundant
eosinophilic cytoplasm, visible nucleoli and mitosis) when
all three markers were negative.
For the analysis of LN metastases, we pre-selected 33
metastatic LNs from 14 melanoma patients. 10 metastatic
LNs were excluded from the analysis because of the pres-
ence of large regions of tumor necrosis (2/10), presence of
excessive melanin pigments rendering analysis impossible
(5/10), tumor metastasis size less than 1 mm2 (1/10) or
tumor metastasis size more than 98% of the entire LN (2/
10). In the 23 remaining metastatic LNs, we deﬁned 2 dif-
ferent zones corresponding to center of tumor and stroma
(Fig. S6B). The center of tumor was determined as previ-
ously described for primary tumors. Stroma was deﬁned as
connective tissue surrounding the tumor cells (present in 14
(61%) metastatic LNs). Finally, we also studied tumor-free
LNs that had been obtained through LN dissection surgery.
We analyzed the total area without deﬁning speciﬁc zones
in these 23 tumor-free LNs (Table S4). Image analyses and
determination of regions were approved by two blinded
experienced pathologists.
Staining quantiﬁcation
ImageScopeTM Aperio software
Whole slide digital images were obtained for each specimen
stained with Chromogenic IHC staining using NanoZoomer
2-HT digital slide scanner (Hamamatsu). The resulting
high-resolution digital images were analyzed with the
ImageScopeTM software, version 12.1 (Aperio Technologies,
Vista, CA, USA), using the pixel positive cell algorithm 9.1
as previously described and validated.48 Brieﬂy, this algo-
rithm detects pixels that match input parameters set for the
algorithm and generates four output values based on the
pixel’s color range: haematoxylin or negative signal (blue in
mark-up image), weak positive (yellow in mark-up image),
positive (orange in mark-up image) and strong positive
(brown in mark-up image) (Fig. S7). Using these parame-
ters, the strong non-speciﬁc (brown) as well as the weak
positive (yellow) signals were considered as debris back-
ground staining, whereas the positive value (orange) was
considered as speciﬁc. Folds, debris, holes were also
removed manually to be exclude from the staining quantiﬁ-
cation analysis. Quantiﬁcation of the staining in the tissue
selected was reported as a relative abundance ratio, which
was based on the number of positive pixels (orange) divided
by the total number of pixels (blue C yellow C orange C
brown). The relative abundance ratio was reported in %
and represented the percentage of density per tissue area
for the quantiﬁed staining. Results obtained were controlled
to match with visual inspection. The pixel positive cell algo-
rithm was applied on primary tumors, tumor-free LNs and
metastatic LNs.
Quantiﬁcation of LECs
LECs are typically identiﬁed by expression of the nuclear
transcription factor Prox-1 and the surface markers podopla-
nin and Lyve-1. However, depending on their tissue location
and state of development, LEC expression of these markers
can be variable, and furthermore, other cell types within the
tumor microenvironment can also express these markers.45,71
Some tumor-associated macrophages express Lyve-1, and
cancer-associated ﬁbroblasts found in the stroma can express
podoplanin. As expected, in our tissue sections, LECs
expressed podoplanin and nuclear Prox-1 in all tissues ana-
lyzed, but these markers were also found in other types of
cells depending on the region evaluated (see result section
and Fig. S1). Consequently, when comparing expression in
the same tissue sections, Prox-1 and podoplanin did not nec-
essarily correlate in the tumor regions (i.e. center of tumor
and invasive margin) (Fig. S8). Indeed, we noticed a positive
trend in peritumoral area and a positive correlation in nor-
mal skin, underlining that the expression of Prox-1 was not
a reliable marker of intratumoral LECs. For validation of our
quantiﬁcation strategy and the identiﬁcation of lymphatic
vessels, we counted the lymphatic vessels by eye in the differ-
ent regions of primary tumors, in the tumor area of meta-
static LNs and in the entire section of non-metastatic LNs by
combining IHC markers (i.e. podoplanin or Prox-1) with
vessel morphology. The counting by eye was done in the
same regions as the automated image analysis, covering the
whole areas. The number of lymphatic vessels per area was
then divided by the total surface area, resulting in lymphatic
vessels per mm2 for each region.
Identiﬁcation of LECs may be improved by simulta-
neously using multiple markers which can be achieved with
multiplex IF techniques. However, good quality stainings
and analysis of wide areas and whole tissue sections is difﬁ-
cult (staining must be homogenous) and was not possible
at the time when this work was done. Therefore, we used
single marker LEC identiﬁcation using IHC, allowing large-
scale assessment and quantiﬁcation. In addition, we used IF
images for illustration purpose and for in-depth analysis of
correlations found in IHC.
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Statistics
To compare only two data sets, unpaired t- tests (normal distri-
bution of data points) or Mann–Whitney U tests (data points
not normally distributed) were used to assess statistical signiﬁ-
cance. To visualize correlations of two different markers, raw
data received from the pixel positive cell algorithm (Image-
ScopeTM, see Image Analysis) were plotted and a line with lin-
ear regression was ﬁtted into the plot. Correlation coefﬁcients
were calculated using Spearman’s non-parametric test. To com-
pare multiple groups, One-Way Kruskal-Wallis non-paramet-
ric tests were applied with post-hoc test Dunn correction. A
two-tailed p value of  0.05 was considered to be signiﬁcant.
Analyses were performed with Prism (version 6.0b, GraphPad
Software, La Jolla, CA, USA). Statistics were approved by a cer-
tiﬁed statistician.
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